By Adria Calatayud

 

Sanofi SA said the U.S. Food and Drug Administration has approved its Altuviiio drug, a once weekly treatment for hemophilia A.

The French pharmaceutical company said this is the first approval of the drug, previously referred to as efanesoctocog alfa, and that regulatory submission in the European Union is expected in the second half of this year.

The FDA had granted priority review to the drug in August and designed it a breakthrough therapy in May.

 

Write to Adria Calatayud at adria.calatayud@dowjones.com

 

(END) Dow Jones Newswires

February 24, 2023 01:18 ET (06:18 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Sanofi
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Sanofi